<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="969">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 27, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00823264</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00008017</org_study_id>
    <nct_id>NCT00823264</nct_id>
  </id_info>
  <brief_title>Phenytoin and Multidose Activated Charcoal</brief_title>
  <official_title>Prospective Randomized Study of Multidose Activated Charcoal in Supratherapeutic Phenytoin Serum Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phenytoin is a medicine used to treat seizures. If too much is taken, patients have ill
      effects including sleepiness, unsteady gait, and eye problems. The amount of drug in their
      system can be measured in their blood. Charcoal is a medicine that can absorb phenytoin. We
      want to see if giving multiple doses of charcoal will quicken the removal of phenytoin from
      the blood. This is theorized to occur as charcoal absorbs phenytoin from across the
      intestines and then is secreted in the stool. Patients will be selected to receive either
      charcoal in multiple doses or no charcoal and their serum levels will be drawn repeatedly to
      follow their level. The different groups will then be compared to see if multidose charcoal
      does indeed increase the elimination of phenytoin from the body.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See above
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time of Elimination of Phenytoin in Patients With Elevated Phenytoin Levels</measure>
    <time_frame>Serum phenytoin levels were obtained every 6 hours for 24 hours then once every 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>We enrolled patients with elevated phenytoin levels into the study with greater than 30 ug/cc. The treatment arm received multiple doses of activated charcoal and the control arm received no activated charcoal. We obtained serum phenytoin levels every 6 hours for 24 hours then once every 24 hours. The time to reach a subtoxic level was determined in each arm by looking at serum phenytoin levels and documenting when it was below 25 ug/cc.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Phenytoin Toxicity</condition>
  <arm_group>
    <arm_group_label>Multiple Doses of Activated Charcoal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 50 grams of activated charcoal by mouth every 4 hours until phenytoin levels drop below 25 ug/cc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Will not receive activated charcoal. Serum levels will be followed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Activated Charcoal</intervention_name>
    <description>50 grams by mouth every 4 hours until serum phenytoin level is less than 25.</description>
    <arm_group_label>Multiple Doses of Activated Charcoal</arm_group_label>
    <other_name>Charcoal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Phenytoin level &gt; 30 mg/L

        Exclusion Criteria:

          -  Age &lt; 18

          -  Known allergy to Activated Charcoal

          -  Pregnant

          -  Inability to take PO drugs

          -  Non English speaking

          -  Inability to give consent

          -  Any prisoners
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carl Skinner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Skinner CG, Chang AS, Matthews AS, Reedy SJ, Morgan BW. Randomized controlled study on the use of multiple-dose activated charcoal in patients with supratherapeutic phenytoin levels. Clin Toxicol (Phila). 2012 Sep;50(8):764-9. doi: 10.3109/15563650.2012.716159. Epub 2012 Aug 17. Erratum in: Clin Toxicol (Phila). 2012 Dec;50(10):1176.</citation>
    <PMID>22897408</PMID>
  </results_reference>
  <verification_date>September 2014</verification_date>
  <lastchanged_date>September 4, 2014</lastchanged_date>
  <firstreceived_date>January 14, 2009</firstreceived_date>
  <firstreceived_results_date>August 14, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Brent W Morgan, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Anticonvulsants</keyword>
  <keyword>Toxicology</keyword>
  <keyword>multidose charcoal</keyword>
  <keyword>phenytoin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Charcoal</mesh_term>
    <mesh_term>Phenytoin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>Will not receive activated charcoal. Serum levels will be followed.</description>
        </group>
        <group group_id="P2">
          <title>Multiple Doses of Activated Charcoal</title>
          <description>Will receive 50 grams of activated charcoal every 4 hours by mouth until phenytoin level is &lt; 25 ug/cc.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>Will not receive activated charcoal. Serum levels will be followed.</description>
        </group>
        <group group_id="B2">
          <title>Multiple Doses of Activated Charcoal</title>
          <description>Will receive 50 grams of activated charcoal by mouth every 4 hours until phenytoin levels are &lt; 25 ug/cc.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="14"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time of Elimination of Phenytoin in Patients With Elevated Phenytoin Levels</title>
        <description>We enrolled patients with elevated phenytoin levels into the study with greater than 30 ug/cc. The treatment arm received multiple doses of activated charcoal and the control arm received no activated charcoal. We obtained serum phenytoin levels every 6 hours for 24 hours then once every 24 hours. The time to reach a subtoxic level was determined in each arm by looking at serum phenytoin levels and documenting when it was below 25 ug/cc.</description>
        <time_frame>Serum phenytoin levels were obtained every 6 hours for 24 hours then once every 24 hours</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Will not receive activated charcoal. Serum levels will be followed.</description>
          </group>
          <group group_id="O2">
            <title>Multiple Doses of Activated Charcoal</title>
            <description>Patients received 50 grams of activated charcoal by mouth every 6 hours until the phenytoin levels was below 25 ug/cc.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time of Elimination of Phenytoin in Patients With Elevated Phenytoin Levels</title>
            <description>We enrolled patients with elevated phenytoin levels into the study with greater than 30 ug/cc. The treatment arm received multiple doses of activated charcoal and the control arm received no activated charcoal. We obtained serum phenytoin levels every 6 hours for 24 hours then once every 24 hours. The time to reach a subtoxic level was determined in each arm by looking at serum phenytoin levels and documenting when it was below 25 ug/cc.</description>
            <units>hours</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="41.1" lower_limit="11.6" upper_limit="196"/>
                  <measurement group_id="O2" value="19.3" lower_limit="13" upper_limit="33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.049</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Brent Morgan</name_or_title>
      <organization>Emory University</organization>
      <phone>404-616-4403</phone>
      <email>bmorg02@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
